When is LYEL's latest earnings report released?
The most recent financial report for Lyell immunopharma, inc. (LYEL) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LYEL's short-term business performance and financial health. For the latest updates on LYEL's earnings releases, visit this page regularly.
What is the operating profit of LYEL?
According to the latest financial report, Lyell immunopharma, inc. (LYEL) reported an Operating Profit of -37.25M with an Operating Margin of -248,353.33% this period, representing a growth of 26.24% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is LYEL's revenue growth?
In the latest financial report, Lyell immunopharma, inc. (LYEL) announced revenue of 15K, with a Year-Over-Year growth rate of -55.88%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does LYEL have?
At the end of the period, Lyell immunopharma, inc. (LYEL) held Total Cash and Cash Equivalents of 125.16M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does LYEL go with three margins increasing?
In the latest report, Lyell immunopharma, inc. (LYEL) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -248,353.33%%, and net margin of -258,973.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LYEL's profit trajectory and future growth potential.
Is LYEL's EPS continuing to grow?
According to the past four quarterly reports, Lyell immunopharma, inc. (LYEL)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of LYEL?
Lyell immunopharma, inc. (LYEL)'s Free Cash Flow (FCF) for the period is -28.38M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 19.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
